1. Opening Hook

Biotechs usually spend years in stealth mode, burning cash like bonfires. Anthem, freshly listed, flipped the script—kicked off FY26 flaunting 38% EBITDA margins and ₹750 Cr in the bank. In a quarter where most CDMOs cry about lumpiness, Anthem called it “exceptional” with a straight face. Investors cheered, but management quickly added: “Don’t expect fireworks every quarter.” Translation: you just saw our Virat Kohli cover drive; next ball might be a dot. Stick around—this story has ADCs, GLP-1s, and enough jargon to make even ChatGPT reboot.

2. At a Glance

• Revenue ₹540 Cr – CRDMO stream ramped up, speciality ingredients chipped in.
• EBITDA ₹214 Cr – Margin 38%; B-school professors fainted in envy.
• PAT ₹136 Cr – 24% margin, rare in India’s CDMO circus.
• Cash ₹785 Cr – Post-IPO treasury heavier than some mid-cap banks.
• Capacity Additions – 54 KL added in Q1, more on the way.
• First Concall – Management dropped more “lumpiness” warnings than Sensex crash memes.

3. Management’s Key Commentary

• “Kicked off FY26 with strong performance.”
  (Translation: IPO money still warm, let’s flex early.)
• “CRDMO revenues ₹452 Cr this quarter.”
  (Translation: CRO is appetizer, CMO is the biryani.)
• “Margins at 38%, PAT at 24%.”
  (Translation: Pharma bros, stop crying about price erosion.)
• “Exceptional quarter, but don’t expect this every time.”
  (Translation: No multi-bagger quarter repeats, sorry.)
• “Peptide capacity added at NeoAnthem.”
  (Translation: Yes, we’re GLP-1 ready—Novo, call us.)
• “Unit 4 expansion groundbreaking done.”
  (Translation: We love capex almost as much as investors love buzzwords.)
• “Top 15–20 year CAGR track record of ~20% intact.”
  (Translation: Chill, we’ll keep compounding like a SIP.)

4. Numbers Decoded

5. Analyst Questions

• Margins sustainable? – Mgmt: “Steady margins, ESOP costs one-off.”
  (Translation: Ignore noise, enjoy 38% EBITDA.)
• Growth outlook? – Mgmt: “20% CAGR track intact.”
  (Translation: Stop dreaming 60% each quarter.)
• Mexico-style